Endpoints at JPM26: Biopharma's Foundational Reset

Your JPM HQ — wherever you are

JANUARY 12 - 13, 2026 | 7:00 AM - 5:00 PM PT
VIRTUAL + SAN FRANCISCO

Starting Monday, biopharma’s top dealmakers, funders, and CEOs will gather to answer the big question: Where’s the money going in 2026?

With a virtual Endpoints at JPM pass, you don’t need to be in San Francisco to stay in the loop. Join us online for exclusive access to in-depth conversations with leaders from Amgen, AbbVie, Merck, PwC, Centerview, and more — streamed straight to you.

GET YOUR FREE VIRTUAL PASS

Virtual programming will run from 8 AM - 12 PM PT each day.

Going to be in San Francisco?
Choose your in-person pass

ALL-ACCESS

Join us in-person on Monday & Tuesday

DAY PASS

Join us in-person on Monday or Tuesday

GROUP PASS

Includes 3 All-Access passes

AGENDA HIGHLIGHTS

On the IPO front, LB Pharmaceuticals CEO Heather Turner made headlines by taking her company public in September, breaking nearly an eight-month dry spell for US biotech listings. She'll give a behind-the-scenes account of why they went for it and how they pulled it off when most companies were still waiting on the sidelines.

Heather Turner
CEO
LB Pharmaceuticals

We'll also hear from Ivana Magovčević-Liebisch, who navigated Vigil Neuroscience through its Sanofi acquisition and is now leading Draig Therapeutics — she'll walk through how that deal came together and how she's thinking about her next chapter.

Endpoints at JPM26 exclusive data: What biopharma leaders really think about 2026

We're unveiling exclusive data from our new Biopharma Sentiment Index (BPSI), drawn from Endpoints readers who sit at the center of industry decision-making. What do executives actually think when surveyed anonymously about funding trajectories, regulatory challenges, and which therapeutic areas will attract capital?

These conversations will set your agenda for navigating what's ahead. Join us.